Company Description
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome.
It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML.
The company was founded in 2007 and is based in Bellaire, Texas.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Peter Nielsen |
Contact Details
Address: 4710 Bellaire Boulevard, Suite 210 Bellaire, Texas 77401 United States | |
| Phone | 832 742 1357 |
| Website | biopathholdings.com |
Stock Details
| Ticker Symbol | BPTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001133818 |
| CUSIP Number | 09057N300 |
| ISIN Number | US09057N3008 |
| Employer ID | 87-0652870 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter H. Nielsen MBA | Co-Founder, Chairman of the Board, Chief Executive Officer, President, Chief Financial Officer and Treasurer |
| Douglas P. Morris | Co-Founder, Director of Investor Relations, Secretary and Director |
| Michael Hickey M.B.A. | Vice President of Clinical Operations |
| Anthony Price | Senior Vice President of Finance, Accounting and Administration |
| Dr. Ana Tari Ashizawa M.B.A., MBA, Ph.D. | Senior Vice President of Research, Development and Clinical Design |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 28, 2024 | ARS | Filing |
| Oct 28, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 28, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 23, 2024 | 424B3 | Prospectus |
| Oct 22, 2024 | EFFECT | Notice of Effectiveness |
| Oct 22, 2024 | D | Notice of Exempt Offering of Securities |